Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS)

Alector Provides Executive Leadership Update

Alector to Present at Upcoming Virtual Healthcare Conferences

Alector Reports Second Quarter 2021 Financial Results

Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation

Alector to Present New Data from Frontotemporal Dementia and Alzheimer’s Disease Programs at the 2021 Alzheimer’s Association International Conference

Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases

Alector to Present at Upcoming Virtual Healthcare Conferences

Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021

Alector to Present at the BofA Securities 2021 Virtual Health Care Conference